Loading
The usual model waits for a patient to complain, by which time an arm has been swollen for a year. The prospective surveillance model measures function before treatment starts and again at set points afterwards, so a small problem is found while it is still small. One costing study put the price of managing early arm swelling at 636 dollars a year against 3,125 dollars for late swelling.
The model was written down in 2012 by a multidisciplinary group convened around breast cancer, and published as a set of papers in the journal Cancer. Its proposal is simple and structural: take a baseline measurement of function before treatment begins, repeat it at defined points during and after treatment, and refer the moment a measure moves. The authors list the impairments it is meant to catch, which is a useful list in itself: "pain, fatigue, upper-extremity dysfunction, lymphedema, weakness, joint arthralgia, neuropathy, weight gain, cardiovascular effects, and osteoporosis".
The cost argument came from the same group. Comparing a surveillance programme with the traditional referral-when-it-is-bad model for breast cancer related arm swelling, and costing both from the 2009 Medicare physician fee schedule, they estimated 636.19 dollars per patient per year to manage early-stage swelling found by surveillance against 3,124.92 dollars per patient per year to treat late-stage swelling found the old way. That is a modelled comparison, not a trial, and the authors say so: they call for analysis of indirect costs and utility before claiming cost-effectiveness.
The electronic version is where the field has moved. An electronic prospective surveillance model asks patients to complete short impairment questionnaires at set points on a phone or web form; a score that crosses a threshold produces self-management material, a community programme or a referral. The REACH system running across four Canadian centres covers breast, colorectal, lymphoma and head and neck cancer and follows patients up to two years after treatment. Its own protocol is careful about the state of the evidence: it says randomised trials show these systems "can effectively manage cancer-related impairments", and then that they "are not routinely embedded into practice and evidence-based approaches to implement them are limited".
The implementation problem is the real one. A 2023 account of running the model in one breast centre describes what it took: clinical pathways, order sets in the electronic record, automated referrals, new staffing models and changed clinic workflows. Its first sentence about uptake is the honest one, that the model "is empirically validated and feasible in practice" but that "implementation into cancer care delivery has languished".
What comes back, and when: nothing, by itself. Surveillance treats no one. Its claim is that the same treatment started earlier works better and costs less, which is well supported for arm swelling and plausible but less tested for the rest of the list.
Impairments after cancer treatment follow a gradient from reversible to fixed. Measuring function at fixed intervals converts the question from whether a patient complains loudly enough to whether a number has moved, which detects the reversible phase. The mechanism is the same as any screening programme, and so are its weaknesses: it finds things that would not have mattered, and it only works if a service exists to refer into.
Query for this technology: (TITLE:"Prospective surveillance: looking for the problem before it becomes a disability" OR ABSTRACT:"Prospective surveillance: looking for the problem before it becomes a disability") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Prospective surveillance: looking for the problem before it becomes a disability, not a curated reading list.
Shares Vocational rehabilitation integrated into cancer care so survivors can return to work, Compression, decongestive therapy and exercise for lymphoedema, Cancer rehabilitation: the discipline that puts function back, Quality of life and the tags rejuvenation, survivorship, rehabilitation.
Shares Scars, stiffness and contracture: shoulders, necks and jaws, Compression, decongestive therapy and exercise for lymphoedema, Cancer rehabilitation: the discipline that puts function back, Quality of life and the tags rejuvenation, survivorship, rehabilitation.
Shares Where rehabilitation is commissioned, and who misses out, Cancer rehabilitation: the discipline that puts function back, Quality of life, Late effects and survivorship toxicity and the tags rejuvenation, survivorship, rehabilitation.
Shares Where rehabilitation is commissioned, and who misses out, Compression, decongestive therapy and exercise for lymphoedema, Quality of life, Late effects and survivorship toxicity and the tags rejuvenation, survivorship, rehabilitation.
Shares Where rehabilitation is commissioned, and who misses out, Cancer rehabilitation: the discipline that puts function back, Quality of life, Survivorship and late effects are neglected and the tags rejuvenation, survivorship, rehabilitation.
Shares Scars, stiffness and contracture: shoulders, necks and jaws, Cancer rehabilitation: the discipline that puts function back, Quality of life, Survivorship and late effects are neglected and the tags rejuvenation, survivorship, rehabilitation.
Shares Scars, stiffness and contracture: shoulders, necks and jaws, Cancer rehabilitation: the discipline that puts function back, Quality of life, Survivorship and late effects are neglected and the tags rejuvenation, survivorship, rehabilitation.
Shares Cancer rehabilitation: the discipline that puts function back, Quality of life, Late effects and survivorship toxicity, Survivorship and late effects are neglected and the tags rejuvenation, survivorship, rehabilitation.